Ikena Oncology IKNA Stock
Ikena Oncology Price Chart
Ikena Oncology IKNA Financial and Trading Overview
| Ikena Oncology stock price | 1.34 USD |
| Previous Close | 6.3 USD |
| Open | 6.32 USD |
| Bid | 0 USD x 1200 |
| Ask | 0 USD x 1000 |
| Day's Range | 6.32 - 6.81 USD |
| 52 Week Range | 1.94 - 7.64 USD |
| Volume | 62.03K USD |
| Avg. Volume | 71.92K USD |
| Market Cap | 239.38M USD |
| Beta (5Y Monthly) | 0.844002 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.63 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 17.67 USD |
IKNA Valuation Measures
| Enterprise Value | 96.04M USD |
| Trailing P/E | N/A |
| Forward P/E | -3.7714286 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 13.642332 |
| Price/Book (mrq) | 1.7722878 |
| Enterprise Value/Revenue | 5.473 |
| Enterprise Value/EBITDA | -1.399 |
Trading Information
Ikena Oncology Stock Price History
| Beta (5Y Monthly) | 0.844002 |
| 52-Week Change | 82.82% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 7.64 USD |
| 52 Week Low | 1.94 USD |
| 50-Day Moving Average | 5.92 USD |
| 200-Day Moving Average | 4.04 USD |
IKNA Share Statistics
| Avg. Volume (3 month) | 71.92K USD |
| Avg. Daily Volume (10-Days) | 77.59K USD |
| Shares Outstanding | 36.27M |
| Float | 17.33M |
| Short Ratio | 3.83 |
| % Held by Insiders | 0.40% |
| % Held by Institutions | 90.34% |
| Shares Short | 279.35K |
| Short % of Float | 1.54% |
| Short % of Shares Outstanding | 0.77% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | -395.83% |
| Gross Margin | -273.45% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -22.83% |
| Return on Equity (ttm) | -40.33% |
Income Statement
| Revenue (ttm) | 17.55M USD |
| Revenue Per Share (ttm) | 0.48 USD |
| Quarterly Revenue Growth (yoy) | 56.99% |
| Gross Profit (ttm) | -48703000 USD |
| EBITDA | -68655000 USD |
| Net Income Avi to Common (ttm) | -66145000 USD |
| Diluted EPS (ttm) | -1.7 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 137.81M USD |
| Total Cash Per Share (mrq) | 3.8 USD |
| Total Debt (mrq) | 5.35M USD |
| Total Debt/Equity (mrq) | 3.96 USD |
| Current Ratio (mrq) | 10.12 |
| Book Value Per Share (mrq) | 3.724 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -74109000 USD |
| Levered Free Cash Flow (ttm) | -47661624 USD |
Profile of Ikena Oncology
| Country | United States |
| State | MA |
| City | Boston |
| Address | 645 Summer Street |
| ZIP | 02210 |
| Phone | 857 273 8343 |
| Website | https://ikenaoncology.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 74 |
Ikena Oncology, Inc. operates as an oncology company that develops precision medicines to biomarker-defined patients with specific unmet needs in the United States. Its lead oncology product candidate is IK-930, a paralog selective inhibitor of the transcriptional enhanced associate domain, a transcription factor in the Hippo signaling pathway. It also develops IK-595, designed to trap MEK and RAF for inhibiting RAS signals than existing inhibitors; and IK-175, a monotherapy and in combination with nivolumab in patients with advanced or metastatic solid tumors, including urothelial carcinomas. Ikena Oncology, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.
Q&A For Ikena Oncology Stock
What is a current IKNA stock price?
Ikena Oncology IKNA stock price today per share is 1.34 USD.
How to purchase Ikena Oncology stock?
You can buy IKNA shares on the NasdaqGM exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Ikena Oncology?
The stock symbol or ticker of Ikena Oncology is IKNA.
Which industry does the Ikena Oncology company belong to?
The Ikena Oncology industry is Biotechnology.
How many shares does Ikena Oncology have in circulation?
The max supply of Ikena Oncology shares is 47.9M.
What is Ikena Oncology Price to Earnings Ratio (PE Ratio)?
Ikena Oncology PE Ratio is now.
What was Ikena Oncology earnings per share over the trailing 12 months (TTM)?
Ikena Oncology EPS is -1.63 USD over the trailing 12 months.
Which sector does the Ikena Oncology company belong to?
The Ikena Oncology sector is Healthcare.
Ikena Oncology IKNA included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| NASDAQ Composite IXIC | 16175.09 USD — |
-1.62
|
3.94B USD — | 16125.33 USD — | 16341.46 USD — | — - | 3.94B USD — |
| NASDAQ Global Market Composite NQGM | 2160.36 USD — |
-2.45
|
— — | 2147.48 USD — | 2200.33 USD — | — - | — — |
| NASDAQ Biotechnology NBI | 4195.13 USD — |
-2.14
|
— — | 4174.1 USD — | 4266.29 USD — | — - | — — |
| NASDAQ HealthCare IXHC | 958.68 USD — |
-2.07
|
— — | 954.08 USD — | 972.42 USD — | — - | — — |
| Stlmt ID NASDAQ Biotechnology NBX | 4604.4 USD — |
-2.98
|
— — | 4555.41 USD — | 4917.8 USD — | — - | — — |
- {{ link.label }} {{link}}